Predicting adverse outcomes in primary Sjögren's syndrome: Identification of prognostic factors

Rheumatology

Volumn 46, Issue 8, 2007, Pages 1359-1362

  Brito Zeron P ^a   Ramos Casals, M ^a,b   Bove, A ^a   Sentis, J ^a   Font, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Cryoglobulins; Hypocomplementaemia; Mortality; Sj gren syndrome; Vasculitis

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CRYOGLOBULIN;

ADULT; ARTICLE; B CELL LYMPHOMA; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CRYOGLOBULINEMIA; DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HYPOCOMPLEMENTEMIA; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PAROTID GLAND DISEASE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCINTISCANNING; SJOEGREN SYNDROME; SURVIVAL; VASCULITIS;

AGED; COMPLEMENT C3; COMPLEMENT C4; CRYOGLOBULINEMIA; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PAROTID GLAND; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; VASCULITIS;

EID: 34547851823     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem079     Document Type: Article

References (31)

1. Fox RI. Sjögren's syndrome. Lancet 2005;366:321-31.
2. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med 2004;164:1275-84.
3. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren's syndrome: New clinical and therapeutic concepts. Ann Rheum Dis 2005;64:347-54.
4. Ramos-Casals M, Font J. Primary Sjögren's syndrome: Current and emergent aetiopathogenic concepts. Rheumatology 2005;44:1354-67.
5. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren's syndrome: A prospective cohort study. Arthritis Rheum 2004;50:1262-9.
6. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7.
7. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pastemack A. A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: Clinical, immunological and epidemiological aspects. Ann Rheum Dis 2001;60:467-72.
8. Kruize AA, Hene RJ, van der Heide A, Bodeutsch C, de Wilde PC, van Bijsterveld OP et al. Long-term follow-up of patients with Sjögren's syndrome. Arthritis Rheum 1996;39:297-303.
9. Martens PB, Pillemer SR, Jacobsson LT, O'Fallon WM, Matteson EL. Survivorship in a population based cohort of patients with Sjögren's syndrome, 1976-1992. J Rheumatol 1999;26:1296-300.
10. Ramos-Casals M, Anaya JM, Garcia-Carrasco M et al. Cutaneous vasculitis in primary Sjögren syndrome: Classification and clinical significance of 52 patients. Medicine 2004;83:96-106.
11. Voulgarelis M, Dafni UG, Isenberg DA, Mousopoulos HM. Malignant lymphoma in primary Sjögren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's syndrome. Arthritis Rheum 1999;42: 1765-72.
12. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of Primary Sjögren's syndrome. Semin Arthritis Rheum 2000;29:296-304.
13. Vitali C, Bombardieri S, Moutsopoulos HM et al. The European Study Group on Diagnostic Criteria for Sjögren's syndrome. Preliminary criteria for the classification of Sjögren's syndrome: Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
14. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
15. Ramos-Casals M, Font J, Garcia-Carrasco M et al. Primary Sjögren syndrome: Hematologic patterns of disease expression. Medicine 2002;81:281-92.
16. Garcia-Carrasco M, Ramos-Casals M, Rosas J et al. Primary Sjögren syndrome: Clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 2002;81:270-80.
17. Jaffe ES, Harris NL, Stain H, Vardiman JW. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
18. Schall GL, Anderson LG, Wolf RO et al. Xerostomia in Sjögren's syndrome. Evaluation by sequential salivary scintigraphy. JAMA 1971;216:2109-16.
19. Davidson BKS, Kelly CA, Griffiths ID. Primary Sjögren's syndrome in the North East of England: A long-term follow-up study. Rheumatology 1999;38:245-53.
20. Bowman SJ. Collaborative research into outcome measures in Sjögren's syndrome. Update on disease assessment. Scand J Rheumatol Suppl 2002;116:23-7.
21. Alexander EL, Amett FC, Provost TT, Stevens MB. Sjögren's syndrome: association of anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities and serologic hyperreactivity. Ann Intern Med 1983;98:155-59.
22. Tsokos M, Lazarou SA, Moutsopoulos HM. Vasculitis in primary Sjögren's syndrome: Histologic classification and clinica presentation. Am J Clin Pathol 1987;88:26-31.
23. Ramos-Casals M, Cervera R, Yagüe J et al. Cryoglobulinemia in primary SS: Prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 1998;28:200-5.
24. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996;39:767-72.
25. Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjögren's syndrome. Rheumatology 2006;45:1012-5.
26. Valesini G, Priori R, Bavoillot D et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome. J Rheumatol 1997;24:2376-80.
27. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren's syndrome: A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796-803.
28. Ramos-Casals M, Brito-Zeron P, Yague J et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2005;44:89-94.
29. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K et al. Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis Rheum 2005;52:2740-50.
30. Steinfeld SD, Tent L, Burmester GR et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: An open-label phase I/II study. Arthritis Res Ther 2006;8:R129.
31. Pers JO, Daridon C, Devauchelle V et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34-9.